10.57
+0.45(+4.45%)
Currency In USD
| Previous Close | 10.12 |
| Open | 10 |
| Day High | 10.94 |
| Day Low | 10 |
| 52-Week High | 27 |
| 52-Week Low | 5.9 |
| Volume | 2.12M |
| Average Volume | 2.13M |
| Market Cap | 767.86M |
| PE | -13.05 |
| EPS | -0.81 |
| Moving Average 50 Days | 9.12 |
| Moving Average 200 Days | 9.27 |
| Change | 0.45 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $658.57 as of November 16, 2025 at a share price of $10.57. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $413.7 as of November 16, 2025 at a share price of $10.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 9:00 PM GMT
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degr
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial resu
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 24, 2025 8:00 PM GMT
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore differentiation of ARV-806 from other G12D targeting ag